Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company. The Company develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Emergent also develops and commercializes therapeutics and other specialty products for hospitals and clinics.

Current Report (Form 8-K | Period ending 2024-12-12)

424B3 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Emergent Biosolutions (EBS US)

Current Report (Form 8-K | Period ending 2024-12-12)

424B3 | Prospectus

S-1/A | IPO Registration (Amendment)

S-1 | IPO Registration

Current Report (Form 8-K | Period ending 2024-11-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)